NDA 219839 · Dizal
Zegfrovy
Sunvozertinib · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewCDER novel approval, Jul 2, 2025: To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy
Last checked: Nov 20, 2026Latest source record: Jul 2, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jul 2, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
2 Phase 3, 9 recruiting
FAERS reports
41
41 serious, 3 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 16, 2026.
1. INDICATIONS AND USAGE ZEGFROVY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] , whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ZEGFROVY is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.1 ) This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )
Mechanism: Sunvozertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds to and inhibits EGFR exon 20 insertion mutations at similar concentrations as wild-type EGFR. In cultured cell models, sunvozertinib inhibited EGFR phosphorylation in cells expressing different EGFR exon 20 insertion mutation variants at approximately 2- to 10-fold lower concentrations than wild-type EGFR signaling inhibition. Sunvozertinib exhibited anti-tumor activity against xenograft models of NSCLC with EGFR exon 20 insertion mutations.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 2, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalLabelLetterReview
2 products under this application
- ZEGFROVY · SUNVOZERTINIB 200MG · TABLET, ORAL · Prescription
- ZEGFROVY · SUNVOZERTINIB 150MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sunvozertinib" as an intervention, any sponsor and status, largest first.
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryPivotal-lookingRecruiting
Dizal (Jiangsu) Pharmaceutical Co., Ltd.Industry
NCT07182682 · 360 participants (planned) · Start Dec 1, 2025 · Primary completion Sep 2029
Drug: sunvozertinib; Matching Placebo · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Changchun, China; Changsha, China · 49 sites in all
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Pivotal-lookingActive, not recruiting
Dizal PharmaceuticalsIndustry
NCT05668988 · 324 participants · Start Dec 13, 2022 · Primary completion Jan 16, 2026
Drug: sunvozertinib; Pemetrexed+carboplatin · For: Non-small Cell Lung Cancer
Sites: Glendale, California; Vallejo, California; Aurora, Colorado · 154 sites in all
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruiting
Dizal PharmaceuticalsIndustry
NCT03974022 · 315 participants · Start Jul 9, 2019 · Primary completion Jul 29, 2024
Drug: Sunvozertinib · For: Non-Small Cell Lung Cancer
Sites: La Jolla, California; Orange, California; Whittier, California · 124 sites in all
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07079475 · 220 participants (planned) · Start Jul 30, 2025 · Primary completion Jun 2028
Drug: DZD6008; Sunvozertinib and 1 more · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Guangzhou, China; Harbin, China · 14 sites in all
- A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT06905197 · 140 participants (planned) · Start May 13, 2025 · Primary completion Sep 2027
Drug: DZD6008; Sunvozertinib · For: Non Small Cell Lung Cancer
Sites: New York, New York; Fairfax, Virginia; Blacktown, Australia · 5 sites in all
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06563999 · 120 participants (planned) · Start Nov 1, 2024 · Primary completion Nov 1, 2027
Drug: Sunvozertinib; Crizotinib and 7 more · For: Lung Cancer Stage III; Mutation
Sites: Guangzhou, China
- Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruiting
Dizal PharmaceuticalsIndustry
NCT05712902 · 104 participants · Start Jul 19, 2021 · Primary completion Oct 17, 2022
Drug: Sunvozertinib · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Changchun, China; Changsha, China · 33 sites in all
Hunan Province Tumor HospitalAcademic, hospital or other
NCT06355609 · 100 participants (planned) · Start Jul 1, 2024 · Primary completion Dec 30, 2025
Drug: sunvozertinib in combination with Anlotinib · For: Non-small Cell Lung Cancer
Sites: Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea6
- decreased appetite4
- mouth ulceration4
- platelet count decreased4
- pneumonia4
- pneumonitis4
- toxic epidermal necrolysis4
- chest discomfort3
- gastric perforation3
- oedema peripheral3
- rash3
- anaemia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 22 |
| 2026 | 18 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations.
Zhou C, Greillier L, Liu G, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial.
Wang M, Fan Y, Sun M, et al. · Lancet Respir Med 2024 · Clinical Trial, Phase II, Multicenter Study
- Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Yang JC, Wang M, Doucet L, et al. · J Clin Oncol 2025 · Randomized Controlled Trial, Multicenter Study
- Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial.
Xu Y, Chen M, Gao X, et al. · Cancer Lett 2025 · Clinical Trial, Phase II
- Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review.
Wen Q, Zhuang Y, Fu S, et al. · Front Pharmacol 2025 · Systematic Review
Sponsor: Dizal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.